OPA1 and migraine disorder: Thus, in this study, we used a lower dosage of NTG (0.1 mg/kg), which was approximately 10 times of the dose used in human migraine model [40] and similar to that used in a naturalistic rat model which clearly demonstrated activation of trigeminovascular system after infusion of clinically-relevant dose of NTG [23].